<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04175886</url>
  </required_header>
  <id_info>
    <org_study_id>2018_38</org_study_id>
    <secondary_id>2019-001159-37</secondary_id>
    <nct_id>NCT04175886</nct_id>
  </id_info>
  <brief_title>Effects of Tofacitinib on Body Composition, Bone Mineral Density and Bone Marrow Adiposity in Patients With Rheumatoid Arthritis: the TOFAT Project</brief_title>
  <acronym>TOFAT</acronym>
  <official_title>Effects of Tofacitinib on Body Composition, Bone Mineral Density and Bone Marrow Adiposity in Patients With Rheumatoid Arthritis: the TOFAT Project</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Inflammatory rheumatic diseases (IRD), such as rheumatoid arthritis, are characterized by
      adverse changes in body composition. Lean mass and bone mineral density are usually reduced
      while adiposity (total fat mass, visceral adiposity…) is increased in comparison with healthy
      controls. Many factors may influence the body composition of those patients such as aging,
      Disease Modifying Anti-Rheumatic Drugs (DMARDs), nutrition and physical activity.

      However, data on body composition and adverse changes under DMARDs in patients with
      rheumatoid arthritis (RA) are actually scarce. This is the case with tofacitinib (targeted
      synthetic DMARD or tsDMARD) while preliminary data let us think that this treatment may
      influence body composition and bone mineral density.

      This study is going to be the first to focus on changes in body composition (fat mass and
      lean mass), bone mineral density and bone marrow adiposity under tofacitinib.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 25, 2020</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Variation in visceral adiposity (VAT or Visceral Adipose Tissue) in cm²</measure>
    <time_frame>Between the measurement before and after 6 months of tofacitinib treatment (difference before/after).</time_frame>
    <description>Variation in visceral adiposity (VAT or Visceral Adipose Tissue) in cm²</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurements of VAT in cm².</measure>
    <time_frame>at baseline</time_frame>
    <description>Measurements of VAT in cm²</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurements of total fat mass (TBF) in kg, total lean mass (TLM) in kg, appendicular lean mass (aLM) in kg</measure>
    <time_frame>at baseline</time_frame>
    <description>Measurements of total fat mass (TBF) in kg, total lean mass (TLM) in kg, appendicular lean mass (aLM) in kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurements of body fat percentage (%)</measure>
    <time_frame>at baseline</time_frame>
    <description>Measurements of body fat percentage (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurements of fat mass index (FMI) in kg/m² and skeletal muscle mass index (SMI) in kg/m²</measure>
    <time_frame>at baseline</time_frame>
    <description>Measurements of fat mass index (FMI) in kg/m² and skeletal muscle mass index (SMI) in kg/m²</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurements of Bone mineral Density (BMD) in g/cm².</measure>
    <time_frame>at baseline</time_frame>
    <description>Measurements of Bone mineral Density (BMD) in g/cm².</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body fat percentage (% between measurement</measure>
    <time_frame>Before and after 6 months of tofacitinib treatment (difference before/after).</time_frame>
    <description>Change in body fat percentage (%) between measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total fat mass (TBF) between measurement</measure>
    <time_frame>Before and after 6 months of tofacitinib treatment (difference before/after).</time_frame>
    <description>Change in total fat mass (TBF) in kg between measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fat mass index (FMI) in kg/m², between measurement</measure>
    <time_frame>Before and after 6 months of tofacitinib treatment (difference before/after).</time_frame>
    <description>Change in fat mass index (FMI) in kg/m², between measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total lean mass (TLM, kg) and appendicular lean mass (aLM) in kg between measurement</measure>
    <time_frame>Before and after 6 months of tofacitinib treatment (difference before/after).</time_frame>
    <description>Change in total lean mass (TLM, kg) and appendicular lean mass (aLM) in kg between measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in skeletal muscle mass index (SMI) in kg/m² between measurement</measure>
    <time_frame>Before and after 6 months of tofacitinib treatment (difference before/after).</time_frame>
    <description>Change in skeletal muscle mass index (SMI) in kg/m² between measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BMD (in g/cm²) at the lumbar spine (L1-L4) and non-dominant total hip between measurement</measure>
    <time_frame>Before and after 6 months of tofacitinib treatment (difference before/after).</time_frame>
    <description>Change in BMD (in g/cm²) at the lumbar spine (L1-L4) and non-dominant total hip between measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of bone remodelling markers (Cross-laps (CTX) and Type I procollagen N-terminal propeptide (P1NP)) between measurement</measure>
    <time_frame>Before and after 6 months of tofacitinib treatment.</time_frame>
    <description>Variation of bone remodelling markers (Cross-laps (CTX) and Type I procollagen N-terminal propeptide (P1NP)) between measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation in leptin (ng/ml) between measurement.</measure>
    <time_frame>Before and after 6 months of tofacitinib treatment</time_frame>
    <description>Variation in leptin (ng/ml) between measurement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in bone marrow adiposity (%) at the lumbar spine between measurement</measure>
    <time_frame>Before and after 6 months of tofacitinib treatment.</time_frame>
    <description>Change in bone marrow adiposity (%) at the lumbar spine between measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation in Short Physical Performance Battery Protocol (SPPB) between measurement</measure>
    <time_frame>Before and after 6 months of tofacitinib treatment.</time_frame>
    <description>Variation in Short Physical Performance Battery Protocol (SPPB) between measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the parameters of the primary outcome and the secondary outcomes (n°2 to 8)</measure>
    <time_frame>Before and after 12 months of tofacitinib treatment.</time_frame>
    <description>Changes in the parameters of the primary outcome and the secondary outcomes (n°2 to 8)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Patients with rheumatoid arthritis</arm_group_label>
    <description>Patients with rheumatoid arthritis with an indication for tofacitinib: 5mgx2 per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy subjects</arm_group_label>
    <description>Healthy subjects matched to cases (1:1) on age (±5 years), sex, and menopausal status for women and body mass index (BMI, ±3 kg/m²)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tofacitinib</intervention_name>
    <description>Patients will be treated with tofacitinib</description>
    <arm_group_label>Patients with rheumatoid arthritis</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood, serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population is composed of adult patients with moderately to severely active RA
        for whom tofacitinib is indicated and who are followed in the department of rheumatology at
        Lille University Hospital
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patient's ≥18 years old with moderately to severely active Rheumatoid Arthritis
             (RA) (ACR/EULAR criteria )

          -  Previously untreated with Janus Kinase (JAK) inhibitors

          -  With an indication for tofacitinib will be eligible.

          -  All patients will have to be treated with tofacitinib either alone or with
             methotrexate. -Healthy volunteers should be ≥18 years old.

        Exclusion Criteria:

          -  • treatment with more than three anti-Tumor Necrosis Factor alpha (TNFα). Patients who
             were receiving anti-TNFα will be required a washout period lasting at least
             five-half-lives before to start tofacitinib,

               -  previously exposed to JAK inhibitors,

               -  patients who were receiving non-anti-TNFα biologics (abatacept, tocilizumab,
                  sarilumab or rituximab) will be required a washout period lasting at least
                  five-half-lives before to start tofacitinib

               -  Concomitant methotrexate (MTX) will be permitted if started ≥3 months prior to
                  study start and at a stable dose (≤25 mg/week) for ≥4 weeks.

               -  history or discovery of an osteoporotic fracture AND/OR T-score≤-3 if ≥50 years
                  AND/OR Z-score ≤-3 if &lt;50 years during the screening phase,

               -  current treatment with oral corticosteroids higher than 10 mg prednisone/day,

               -  pathologies or treatments that could affect the bone metabolism (breast cancer
                  with aromatase inhibitors, gastrointestinal malabsorption, stomach cancer,
                  primary hyperparathyroidism, uncontrolled hyperthyroidism…),

               -  weight&gt; 160 kg,

               -  patients on restrictive diets or considering such a diet during the study period,

               -  patients with an intense exercise program or planning to benefit from it during
                  the study period,
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Guillaume Letarouilly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Guillaume Letarouilly, MD</last_name>
    <phone>0320445962</phone>
    <phone_ext>+33</phone_ext>
    <email>jg.letarouilly@chru-lille.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lille University Hospital</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Guillaume Letarouilly, DR</last_name>
      <phone>+33320446926</phone>
      <email>jeanguillaume.letarouilly@chru-lille.fr</email>
    </contact>
    <contact_backup>
      <last_name>Julien Paccou, PR</last_name>
      <phone>+33320446926</phone>
      <email>julien.paccou@chru-lille.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Dodington DW, Desai HR, Woo M. JAK/STAT - Emerging Players in Metabolism. Trends Endocrinol Metab. 2018 Jan;29(1):55-65. doi: 10.1016/j.tem.2017.11.001. Epub 2017 Nov 27. Review.</citation>
    <PMID>29191719</PMID>
  </reference>
  <reference>
    <citation>Fleischmann RM, Huizinga TW, Kavanaugh AF, Wilkinson B, Kwok K, DeMasi R, van Vollenhoven RF. Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis. RMD Open. 2016 Jul 26;2(2):e000262. doi: 10.1136/rmdopen-2016-000262. eCollection 2016.</citation>
    <PMID>27493790</PMID>
  </reference>
  <reference>
    <citation>Tatsumi Y, Nakao YM, Masuda I, Higashiyama A, Takegami M, Nishimura K, Watanabe M, Ohkubo T, Okamura T, Miyamoto Y. Risk for metabolic diseases in normal weight individuals with visceral fat accumulation: a cross-sectional study in Japan. BMJ Open. 2017 Jan 16;7(1):e013831. doi: 10.1136/bmjopen-2016-013831.</citation>
    <PMID>28093438</PMID>
  </reference>
  <results_reference>
    <citation>Book C, Karlsson MK, Akesson K, Jacobsson LT. Early rheumatoid arthritis and body composition. Rheumatology (Oxford). 2009 Sep;48(9):1128-32. doi: 10.1093/rheumatology/kep165. Epub 2009 Jul 13.</citation>
    <PMID>19602478</PMID>
  </results_reference>
  <results_reference>
    <citation>Haugeberg G, Uhlig T, Falch JA, Halse JI, Kvien TK. Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register. Arthritis Rheum. 2000 Mar;43(3):522-30.</citation>
    <PMID>10728744</PMID>
  </results_reference>
  <results_reference>
    <citation>Toussirot É, Mourot L, Dehecq B, Wendling D, Grandclément É, Dumoulin G; CBT-506. TNFα blockade for inflammatory rheumatic diseases is associated with a significant gain in android fat mass and has varying effects on adipokines: a 2-year prospective study. Eur J Nutr. 2014 Apr;53(3):951-61. doi: 10.1007/s00394-013-0599-2. Epub 2013 Oct 31.</citation>
    <PMID>24173963</PMID>
  </results_reference>
  <results_reference>
    <citation>Marouen S, Barnetche T, Combe B, Morel J, Daïen CI. TNF inhibitors increase fat mass in inflammatory rheumatic disease: a systematic review with meta-analysis. Clin Exp Rheumatol. 2017 Mar-Apr;35(2):337-343. Epub 2016 Dec 13. Review.</citation>
    <PMID>27974099</PMID>
  </results_reference>
  <results_reference>
    <citation>Engvall IL, Tengstrand B, Brismar K, Hafström I. Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomised study over 21 months. Arthritis Res Ther. 2010;12(5):R197. doi: 10.1186/ar3169. Epub 2010 Oct 21.</citation>
    <PMID>20964833</PMID>
  </results_reference>
  <results_reference>
    <citation>Tournadre A, Pereira B, Dutheil F, Giraud C, Courteix D, Sapin V, Frayssac T, Mathieu S, Malochet-Guinamand S, Soubrier M. Changes in body composition and metabolic profile during interleukin 6 inhibition in rheumatoid arthritis. J Cachexia Sarcopenia Muscle. 2017 Aug;8(4):639-646. doi: 10.1002/jcsm.12189. Epub 2017 Mar 18.</citation>
    <PMID>28316139</PMID>
  </results_reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>November 20, 2019</study_first_submitted>
  <study_first_submitted_qc>November 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2019</study_first_posted>
  <last_update_submitted>June 24, 2020</last_update_submitted>
  <last_update_submitted_qc>June 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rheumatoid arthritis</keyword>
  <keyword>tofacitinib</keyword>
  <keyword>body composition</keyword>
  <keyword>bone marrow adiposity</keyword>
  <keyword>bone marrow density</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tofacitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

